Key result
Glycoprotein IIb/IIIa receptor blockade improved acetylcholine-induced vasodilation and L-NMMA responses in patients with symptomatic coronary artery disease.
Why the study?
Does glycoprotein IIb/IIIa receptor blockade improve endothelial vasomotor function and NO bioactivity in patients with symptomatic coronary artery disease?
Population
40 patients with symptomatic coronary artery stenosis studied before planned percutaneous coronary…
Comparison
Glycoprotein IIb/IIIa receptor blockade vs Baseline
Design
Cohort
Follow-up
Acute (during infusion and 6 hours post-infusion)
Authors
Loading...
Should not change CAD management; leaves open whether GP IIb/IIIa blockade confers endothelial benefit warranting prospective trials.
Does glycoprotein IIb/IIIa receptor blockade improve endothelial vasomotor function and NO bioactivity in patients with symptomatic coronary artery disease?
Glycoprotein IIb/IIIa receptor blockade acutely improves endothelial function and nitric oxide bioavailability in patients with coronary artery disease, suggesting a mechanism for its microvascular benefits.
Heitzer et al. (2003) studied Coronary artery disease (n=40). Glycoprotein IIb/IIIa receptor blockade (tirofiban or eptifibatide) vs. Baseline (before blockade) was evaluated on Endothelium-dependent and -independent vasodilation (forearm blood flow responses). Glycoprotein IIb/IIIa receptor blockade improved acetylcholine-induced vasodilation and L-NMMA responses in patients with symptomatic coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: